Navigation Links
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
Date:5/11/2009

he development of FDA-defined valvulopathy; the decline of Arena's research and development expenses; the planned reduction of Arena's workforce, including the expected size, timing, related charges and savings, and other expected impact of such reduction; Arena's ability to raise additional funds, including through its agreement with Azimuth; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs, the charges related to the recent reduction in Arena's workforce may be greater than anticipated, Arena may not realize the savings expected from this reduction, results of clinical trials or preclinical studies may not be predictive of future results, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing and ability of Arena to receive regulatory approval for its drug candidates, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be requ
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
2. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
3. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
6. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
7. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... York (PRWEB) February 26, 2015 On ... dedicated to building a nationwide Clostridium difficile (C. diff) ... C. diff burden study by the Centers for Disease ... diff caused almost half a million infections among Americans ... U.S. nursing homes. , The study also estimates ...
(Date:2/26/2015)... February 26, 2015 Phosphate ... PEACH, the first pivotal trial of PT20 in ... kidney disease (DD-CKD), has completed as the pre-specified ... PT20, invented by leading UK-based scientists from the ... Therapeutics, is a novel phosphate binder that is ...
(Date:2/25/2015)... 25, 2015 truBrain , creator ... in this week,s Power Pitch segment of CNBC,s  ... the company,s traction and growth strategy, as well ... funding site CircleUp. The segment highlights ... validated by neurotechnology, while also discussing its decision ...
(Date:2/25/2015)... KONG, Feb. 25, 2015 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2015 ended December 31, 2014. Third Quarter ... third quarter of fiscal 2015 increased by 10.7% to ...
Breaking Biology Technology:Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3CNBC's Power Lunch Features Neurotechnology Start-up truBrain 2China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 2China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 3China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 4China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 5China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 6China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 7China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 8China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 9China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 10China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 11China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 12China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 13China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 14China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 15China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 16China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 17China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 18China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 19China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 20China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 21China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 22
... ... (DOE) Argonne National Laboratory has been awarded the HPCwire,s Readers, Choice Award for Best ... HPCwire, at the annual Supercomputing Conference (SC09), currently ongoing in Portland, Ore. , ... Portland, OR (Vocus) Nov. ...
... Nov. 17 Vivakor, Inc. (OTC Bulletin Board: VIVK) today ... shares of common stock of HealthAmerica, Inc., a Nevada corporation ... stock. Each Vivakor shareholder will be entitled to receive ... Vivakor common stock beneficially owned on the record date. ...
... BEACH, Calif. and HAMILTON, New Zealand, Nov. 17 ... for DNA extraction and other life sciences applications, today ... that its forensic GEM(®) Saliva DNA extraction kit ... DNA from buccal swab samples compatible with high-throughput PCR ...
Cached Biology Technology:Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 2Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 3Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 4Vivakor, Inc. Announces Stock Dividend 2Vivakor, Inc. Announces Stock Dividend 3Vivakor, Inc. Announces Stock Dividend 4Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygem's forensicGEM(R) Kit is a Reliable, Rapid Method for Extracting DNA From Saliva 2Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygem's forensicGEM(R) Kit is a Reliable, Rapid Method for Extracting DNA From Saliva 3Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygem's forensicGEM(R) Kit is a Reliable, Rapid Method for Extracting DNA From Saliva 4
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... Medical Center and colleagues at four other medical centers ... genes that may contribute to early atherosclerosis. , ... early adult life who have a genetic predisposition to ... heart disease and stroke sooner and more aggressively," said ...
... may one day help physicians detect cancerous tumors during ... to group together inside cancerous tumors, creating masses with ... a magnetic resonance imaging (MRI) machine. , The work ... of Angewandte Chemie International Edition, one of the world's ...
... increased plant respiration in response to higher global temperatures ... into account plants' ability to adjust to changing conditions, ... In a Perspectives paper published April 28 by Science, ... suggesting that about 9 percent more carbon will be ...
Cached Biology News:Scientists work to identify genes that contribute to early heart attack risk 2MIT nanoparticles may help detect, treat tumors 2Plants' role in global warming re-examined 2
... DNA Visualizer DX's sensitivity of DNA detection has ... band in an agarose gel can be detected ... kit can be purified by organic solvent extraction ... commercially kits worked well.) DNA excised from ...
... a modular, highly scalable, automated high throughput ... 3ml industry standard SPE cartridges, the RapidTrace ... less than two hours unattended. Each module ... up to 10 modules can be connected ...
... evolutionarily conserved form of cell suicide, which ... central component of this process is a ... These enzymes participate in a series of ... pro-apoptotic signals and result in the cleavage ...
... is manufactured for DNA purification from agarose ... UV light. The Purification of DNA from ... DNA-cloning work. The conventional method of visualizing ... UV light damages DNA and significantly decreases ...
Biology Products: